| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | S. Thorsen | |
| P2860 | cites work | Biochemistry of human plasminogen | Q71283013 |
| Beta(Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E | Q71348518 | ||
| Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis | Q72815075 | ||
| Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin | Q28366715 | ||
| Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin | Q28647066 | ||
| Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator | Q35591933 | ||
| The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease | Q37861987 | ||
| Human fibrinogen | Q39641908 | ||
| Fibrin crosslinks and lysis rates | Q39652107 | ||
| On the Kinetics of the Reaction between Human Antiplasmin and Plasmin | Q39849682 | ||
| On the specific interaction between the lysine-binding sites in plasmin and complementary sites in α2-antiplasmin and in fibrinogen | Q39889687 | ||
| Inhibitors of the Fibrinolytic Enzyme System | Q40109416 | ||
| Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis | Q40512234 | ||
| Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain. | Q41106800 | ||
| Quenching of the amidolytic activity of one-chain tissue-type plasminogen activator by mutation of lysine-416. | Q41194174 | ||
| Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions | Q41774337 | ||
| The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function | Q41828771 | ||
| Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator | Q41871005 | ||
| Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of α 2-plasmin inhibitor | Q41899454 | ||
| Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator | Q42848184 | ||
| Zymogen-activation kinetics. Modulatory effects of trans-4-(aminomethyl)cyclohexane-1-carboxylic acid and poly-D-lysine on plasminogen activation | Q42848778 | ||
| Structural requirements of position A alpha-157 in fibrinogen for the fibrin-induced rate enhancement of the activation of plasminogen by tissue-type plasminogen activator | Q42861714 | ||
| Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. | Q50909873 | ||
| Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. | Q52430703 | ||
| Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. | Q52657289 | ||
| The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage. | Q55060368 | ||
| C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen | Q67276498 | ||
| Binding site of alpha 2-plasmin inhibitor to plasminogen | Q68248075 | ||
| The course and prerequisites of Lys-plasminogen formation during fibrinolysis | Q68407284 | ||
| Binding of tissue-type plasminogen activator to lysine, lysine analogues, and fibrin fragments | Q69249522 | ||
| Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2 | Q70398583 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fibrinolysis | Q1410794 |
| history and philosophy of science | Q5774812 | ||
| plasminogen | Q107129060 | ||
| P1104 | number of pages | 12 | |
| P304 | page(s) | 52-63 | |
| P577 | publication date | 1992-12-01 | |
| 1992-12-04 | |||
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis | |
| The Mechanism of Plasminogen Activation and the Variability of the Fibrin Effector during Tissue‐type Plasminogen Activator—mediated Fibrinolysis | |||
| P478 | volume | 667 |
| Q36651337 | A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo. |
| Q53169227 | Antithrombosis activity of protocatechuic and shikimic acids from functional plant Pinus densiflora Sieb. et Zucc needles. |
| Q74272200 | Effects of a fucoidan on the activation of plasminogen by u-PA and t-PA |
| Q59121305 | Fibrin gel as an injectable biodegradable scaffold and cell carrier for tissue engineering |
| Q36710526 | Fibrin structures during tissue-type plasminogen activator-mediated fibrinolysis studied by laser light scattering: relation to fibrin enhancement of plasminogen activation. |
| Q36101288 | Fibrinogen and fibrin. |
| Q35039847 | Fibrinolysis and the control of blood coagulation |
| Q73502284 | Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation |
| Q44405157 | Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces |
| Q49853329 | Liposomes for the delivery of streptokinase |
| Q40406417 | Mechanisms of physiological fibrinolysis |
| Q34013442 | Molecular basis of thrombolytic therapy |
| Q33768031 | New insights into the role of Plg-RKT in macrophage recruitment |
| Q41666794 | Pathophysiology and management of subretinal hemorrhage |
| Q27317618 | Physical determinants of fibrinolysis in single fibrin fibers |
| Q37609916 | Plasminogen receptors: the first quarter century |
| Q52844208 | Plasminogen-receptor KT : plasminogen activation and beyond. |
| Q41958435 | SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats |
| Q37780797 | Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems |
| Q33635164 | The combined use of kartogenin and platelet-rich plasma promotes fibrocartilage formation in the wounded rat Achilles tendon entheses |
| Q34786346 | Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life |
| Q41667008 | Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease |
| Q30757818 | Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. |
Search more.